Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergia.

Providing evidence-based psychiatric care and advanced TMS therapy for adults experiencing depression, anxiety, and treatment-resistant mood disorders.